SCHEDULE 13G: Baker Bros. Advisors Discloses Significant 9.95% Stake in Neurogene Inc.

Baker Bros. Advisors LP and its affiliates have disclosed a beneficial ownership of approximately 9.95% in Neurogene Inc.'s common stock as of March 31, 2025, through a Schedule 13G filing.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Neurogene Inc.
• As of March 31, 2025, Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC each beneficially own 1,486,200 shares of Neurogene Inc. Common Stock, representing 9.95% of the class.
• Julian C. Baker and Felix J. Baker each beneficially own 1,486,313 shares, representing 9.96% of the class.
• The beneficial ownership is based on 14,929,566 shares of Common Stock outstanding as of March 18, 2025, as reported in Neurogene Inc.'s Form 10-K filed on March 24, 2025.
• The shares are primarily held by Baker Brothers Life Sciences, L.P. (1,357,917 shares or 9.1%) and 667, L.P. (125,783 shares or 0.84%), with the Adviser having sole voting and dispositive power over these shares.
• The reported ownership also includes 2,500 shares held by M. Cantey Boyd, a full-time employee of the Adviser, from the exercise of stock options received as director's compensation for her previous service on Neurogene Inc.'s board, with the pecuniary interest assigned to the Funds.
• The Reporting Persons also hold Prefunded Warrants, but these are not currently exercisable due to a beneficial ownership limitation (Maximum Percentage of 4.99%), which can be increased to 19.99% with 61 days' notice.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, the presence of a significant stake by a reputable biotech investor like Baker Bros. Advisors is generally viewed favorably by the market as a vote of confidence in the company's prospects. There are no negative disclosures within the filing itself.

Positives

• The disclosure of a significant stake by Baker Bros. Advisors, a prominent institutional investor specializing in biotechnology, can be viewed as a vote of confidence in Neurogene Inc.'s prospects.
• The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, indicating a passive, long-term investment intent.

Risks

• The Prefunded Warrants held by the Reporting Persons are subject to a beneficial ownership limitation (Maximum Percentage of 4.99%, extendable to 19.99% after 61 days notice), which means they cannot be exercised if it would cause the holders to exceed this threshold, potentially limiting the immediate conversion of these warrants into common stock.

Future Outlook

The document is a beneficial ownership report (Schedule 13G) and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic plans. It primarily details the current ownership stake of Baker Bros. Advisors and its affiliates.

Management Comments

• The document does not contain direct quotes or paraphrased statements from Neurogene Inc. management. It includes a certification from Baker Bros. Advisors LP that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

Baker Bros. Advisors is a well-known investment firm specializing in the biotechnology and life sciences sectors. Their significant stake in Neurogene Inc., a company focused on gene therapies, aligns with broader industry trends of increasing investment in innovative biotech firms, particularly those developing advanced therapeutic modalities like gene therapy. This filing indicates continued institutional confidence in the sector and potentially in Neurogene's specific pipeline or technology.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is a regulatory requirement for passive investors acquiring more than 5% of a company's stock.
• The ownership percentage of approximately 9.95% by Baker Bros. Advisors is a substantial passive stake, typical for large institutional investors in the biotech space who often take significant positions in promising early to mid-stage companies.
• While no specific comparable companies or projects are mentioned in this filing, Baker Bros. Advisors has a history of similar significant investments in other gene therapy and biotechnology companies, such as Sarepta Therapeutics (SRPT) or Incyte Corporation (INCY), where they have also held substantial, long-term positions, indicating a consistent investment strategy within the industry.

Management Changes

Corporate Governance

Related Party Transactions

• M. Cantey Boyd, a full-time employee of Baker Bros. Advisors, previously served on Neurogene Inc.'s board of directors and received stock options as director's compensation. The pecuniary interest in the shares from these options is assigned to the Funds managed by Baker Bros. Advisors, not Ms. Boyd, due to the firm's internal policy.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Baker Bros. Advisors could be perceived positively, potentially increasing investor confidence and attracting further investment.
• Employees, Customers, Suppliers, Creditors: The filing does not contain information directly impacting these stakeholders.

Key Dates

Keywords

Neurogene Inc., Baker Bros. Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Biotech Investment, Institutional Investor, SEC Filing, NGRX, Prefunded Warrants